The GALAXY-1 Project

Healthy Clinical Trial

Official title:

The GALAXY-1 Project: Galactose - the Ideal Carbohydrate Supplement for Exercise

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05986500
• Other study ID #: 1-10-72-49-23
• Status: Recruiting
• Phase: N/A
• Start date: February 12, 2024
• Est. completion date: May 31, 2025

Study information

• Verified date: August 2023
• Source: University of Aarhus
• Contact: Thien V Luong, MD
• Phone: +4531513750
• Email: thiluo[@]clin.au.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

"The understanding of the two sugars, glucose and fructose, has been thoroughly investigated regarding their impact on human metabolism during exercise. The consumption of the sugar galactose is an intriguing alternative and can be beneficial, especially for individuals with type 1 Diabetes, as it reduces the need for insulin to maintain normal blood sugar levels. Additionally, galactose oxidation rates during exercise are only 50-60% compared to glucose, primarily due to liver storage and/or the requirement for conversion to glucose in the liver before oxidation. This delay in metabolism can prevent hyperglycemia before exercise and provide extended protection against episodes of hypoglycemia during and after exercise through a moderate and prolonged glycemic response. The purpose of this experiment is to investigate whether galactose is taken up by skeletal muscles and the heart in response to exercise or hyperinsulinemia. Using non-invasive 18F-FDGal PET, the investigators will examine this in a randomized controlled study design. The results could contribute to updating dietary recommendations, particularly for individuals with type 1 diabetes who struggle to maintain normal blood sugar levels during and after exercise."

Description:

It is generally accepted that saccharides have to be converted into glucose before they can be oxidized and used to produce energy. As a result, non-glucose saccharides affect blood glucose levels differently than glucose. For example, the saccharide fructose requires hepatic conversion to glucose, causing more constant blood sugar levels and less risk of both glucose excursions and hypoglycemia during exercise. However, metabolization of fructose increases the risk of developing nonalcoholic fatty liver disease due to the stimulation of de novo lipogenesis and blocking of β-fatty acid oxidation. Consequently, a different carbohydrate source with the same glycemic profile as fructose but without the undesirable hepatic effects would be preferable. Galactose is the third of the three quantitively important dietary monosaccharides in a regular Western diet. Lactose (disaccharide of galactose and glucose) from dairy products is the primary source of dietary galactose, but galactose is also found in other food sources such as fruits and vegetables. While the impact of glucose and fructose on human metabolism has been extensively studied, there is limited knowledge of the effects of galactose as a nutritional supplement during or before exercise, and it is also unknown whether it can have clinical applications. Intake of galactose or lactose instead of glucose prior to exercise may be advantageous, particularly for individuals with diabetes, since it lowers the insulin requirement to maintain euglycemia. Furthermore, galactose oxidation rates during exercise are only 50-60% compared to glucose, presumably due to hepatic storage and/or a requirement for conversion to glucose in the liver before oxidation. This delay in end-point metabolism could prevent hyperglycemia prior to exercise and at the same time provide prolonged protection from hypoglycemia during and after exercise via the prolonged and moderated glycemic response. In line with this, a recent study from the investigators' collaborator Gareth Wallis's group showed that lactose ingestion in relation to exercise increased fat oxidation and lowered carbohydrate oxidation compared to sucrose ingestion. Accordingly, ingestion of the lactose component - galactose - instead of regular glucose-containing carbohydrates is an intriguing option if blood glucose excursions are to be avoided. However, it is still unclear whether the beneficial metabolic effects of galactose are all caused by the hepatic delay in conversion to glucose or if galactose is also used directly by skeletal muscle as a source of energy. To address this, the investigators recently performed positron emission tomography (PET) pilot studies in two pigs using the galactose analogue 18F-FDGal to measure insulin-stimulated skeletal and cardiac muscle galactose uptake. Although muscle galactose uptake was clearly less than for glucose, it was evident that some uptake can be stimulated by insulin, particularly in the heart. These preliminary data question the current perception that galactose requires conversion to glucose in the liver before it can be utilized as a source of energy. However, studies in anesthetized pigs obviously cannot determine whether a similar direct muscle uptake of galactose can be stimulated by exercise per se, as is the case for glucose. Purpose: The purpose of this experiment is to investigate whether galactose is: 1) taken up by skeletal muscle and extra-hepatic organs, 2) if galactose uptake is affected by prior high intensity exercise with the purpose of depleting glycogen in the working skeletal muscle, and 3) if and to what extent insulin stimulates galactose uptake. Methods: Eight healthy participants will be studied twice in randomized order with 18F-FDGal PET scans during saline infusion (study day 1), and during a hyperinsulinemic-euglycemic clamp (study day 2). To stimulate galactose uptake in the femoral skeletal muscles, each participant will perform a 60-minute one-legged exercise prior to the PET scan. The non-exercised leg will serve as a control to quantify exercise-stimulated galactose uptake (Figure 2). During each study day, participants will receive a galactose infusion (bolus: 6 mmol, infusion rate: 1 mmol/min) to mimic concentrations of galactose similar to what can be achieved after galactose ingestion (1-2 mmol/L) (10). This design allows the investigators to quantify both the independent and combined effects of insulin and exercise on galactose uptake in skeletal muscle. Volunteers: Inclusion criteria: 1. Age 50-75 years 2. Males or post-menopausal females 3. BMI 18.5-30 kg/m2 Exclusion criteria: 1. Clinically significant heart, lung, kidney, liver, endocrine, or malignant disease based on information obtained during an initial screening visit as well as blood samples 2. Blood donation within the last 3 months 3. Smoking 4. Alcohol- or substance abuse 5. Participation in other clinical trials involving ionizing radiation within the last 6 months 6. Claustrophobia 7. Not being physically able to exercise one leg for one hour

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 8
• Est. completion date: May 31, 2025
• Est. primary completion date: November 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age 50-75 years

2. Male or post-menopausal female

3. BMI 18.5-30 kg/m2

Exclusion Criteria:

1. Clinically significant heart, lung, kidney, kidney, liver, endocrine or malignant disease based on information obtained during an initial screening visit as well as blood samples

2. Blood donation within the last 3 months

3. Smoking

4. Alcohol- or substance abuse

5. Participation in other clinical trials involving ionizing radiation within the last 6 months

6. Claustrophobia

7. Not being physically able to exercise one leg for one hour

Related Conditions & MeSH terms

• Healthy

Intervention

Other:
• Galactose
The participants will receive a galactose infusion (bolus: 6 mmol, infusion rate: 1 mmol/min)
• No intervention
The participants will receive a saline infusion

Locations

Country	Name	City	State
Denmark	Aarhus University Hospital	Aarhus N	Jutland

Sponsors (1)

Lead Sponsor	Collaborator
University of Aarhus

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Galactose uptake in skeletal muscle	Skeletal muscle galactose uptake rate (µmol/min/g) measured by 2-(18)F-fluoro-2-deoxy-d-galactose (18F-FDGal)	Measurements will be made on each of the two study days
Secondary	Cardiac galactose uptake	Cardiac galactose uptake rate (µmol/min/g) measured by 2-(18)F-fluoro-2-deoxy-d-galactose (18F-FDGal)	Measurements will be made on each of the two study days
Secondary	Hepatic galactose uptake	Hepatic galactose uptake rate (µmol/min/g) measured by 2-(18)F-fluoro-2-deoxy-d-galactose (18F-FDGal)	Measurements will be made on each of the two study days
Secondary	Plasma glucose levels	Measured in blood samples	Measurements will be made on a screening day and during each of the two study days
Secondary	Skeletal muscle arterio-venous galactose balance	Differences in arterio-venous galactose concentrations taken through catheters in both vv. famoralis and a. radialis	Measurements will be mader during each of the two study days